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Tissue hypoxia and reoxygenation (HR) remain of the main 
causes of permanent or transient damage with serious implications 
on adjacent organs and certainly on patients’ health. Although 
important progress has been made regarding the usage of 
erythropoietin (Epo) in managing this kind of damages, satisfactory 
answers have not been given yet to fundamental questions, as, by 
what velocity this factor acts, when it should be administered, and in 
which dosage. The particularly satisfactory action of Epo in stem 
blood cells recovery has been noted in several performed 
experiments. However, just few relative reports were found 
concerning Epo trial in HR experiments, not covering completely this 
particular matter. A meta-analysis of 14 published seric variables, 
coming from the same experimental setting, tried to provide a 
numeric evaluation of the Epo efficacy at the same endpoints (Table 
1).  
 
Table 1: The erythropoietin (Epo) influence (+SD) on the levels of some seric1 variables concerning reperfusion (rep) time 
 
     Variable 1h rep p-value 1.5h rep p-value 2h rep 
p-
value 




white blood cells          +24.01%±13.38% 0.1012 +22.09%±9.11% 0.0351 +20.17%±12.94% 0.0902 +14.63%±5.40% 0.0080 
hematocrit +0.14%±2.89% 0.9626 -0.61%±2.37% 0.8072 -1.37%±4.05% 0.7485 +0.24%±1.38% 0.8586 
mean corpuscular 
hemoglobin 
+0.01%+1.29% 0.9904 +0.67%±0.80% 0.3549 +1.34%±1.08% 0.1509 -0.36%±0.47% 0.4430 
platelet distribution 
width 
+1.60%±0.80% 0.0765 +1.36%±0.58% 0.0205 +1.13%±0.74% 0.1152 +0.37%±0.37% 0.0615 
plateletcrit -16.47%±10.40% 0.0921 -13.74%±7.01% 0.0158 -11.01%±7.34% 0.0882 -6.88%±3.69% 0.0615 
uric acid                        +10.13%±15.10% 0.4917 +15.86%±10.21% 0.1408 +21.59%±15.45% 0.1940 +9.33%±6.16% 0.1264 
total protein                -0.02%±2.47% 0.9904 -1.27%±1.51% 0.3721 -2.52%±2.03% 0.1509 -0.68%±2.48% 0.4430 
alkaline phosphatase   +0.20%±18.57% 0.9904 +10.70%±12.78% 0.3549 +21.20%±17.11% 0.1509 +5.79%±7.72% 0.4430 
acid phosphatase          +0.06%±5.79% 0.9904 +3.11%±3.71% 0.3172 +6.16%±4.97% 0.1509 +1.68%±2.23% 0.4430 
CPK +0.15%±14.09% 0.9904 +7.91%±9.44% 0.3549 +15.67%±12.65% 0.1509 +4.28%±5.70% 0.4430 
LDH +0.08%±7.92% 0.9904 +4.48%±5.35% 0.3549 +8.89%±7.17% 0.1509 +2.42%±3.22% 0.4430 
Sodium +0.72%±0.74% 0.3054 +0.21%±0.63% 0.7136 -0.29%±1.09% 0.7670 -0.11%±0.38% 0.7531 
phosphorus +1.92%±5.25% 0.6982 +3.95%±3.35% 0.2100 +5.98%±4.81% 0.2930 +2.45%±2.01% 0.2168 
progesterone -0.20%±18.65% 0.9904 -8.86%±10.58% 0.3549 -17.53%±14.15% 0.1509 -4.79%±6.39% 0.4430 
Mean +1.59%±8.41% 0.6900 +3.27%±9.12% 0.3147 +4.95%±11.82% 0.2394 +2.02%±5.41% 0.3704 
 
Abstract 
Aim and objective: The aim of this experimental study was to examine the effect of 
erythropoietin on rat model and particularly in a hypoxia reoxygenation (HR) protocol. 
The effect of that molecule was studied biochemically using blood mean albumins levels. 
Materials and methods: 40 rats of mean weight 247.7 g were used in the study. Albumins 
levels were measured at 60 min (groups A and C) and at 120 min (groups B and D) of 
reoxygenation. Erythropoietin was administered only in groups C and D. 
Result: Results were that Epo administration significantly decreased the albumins levels 
by 9.28%+3.20% (p=0.0054). Reperfusion time non-significantly increased the albumins 
levels by 3.09%+3.52% (p= 0.3405). However, erythropoietin administration and 
reperfusion time together produced a significant combined effect in keeping decreased the 
albumins levels by 5.37%+2.73% (p= 0.0072). 
Conclusions: Conclusions are that erythropoietin administration whether it interacted or 
not with reoxygenation time, has significant decreasing effects on albumins levels in a 
short-term context of 2 hours.  
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Furthermore, several publications addressed trials of 
other similar molecules of growth factors to which the studied 
molecule also belongs to. 
The aim of this experimental study was to examine the 
effect of Epo on rat model and particularly in a liver ischemia 
reperfusion (IR) protocol. The effect of that molecule was studied by 
measuring the blood mean albumins levels.  
 
2. Materials and methods 
2.1 Animal preparation 
This experimental study was lisenced by Veterinary 
Address of East Attiki Prefecture under 3693/12-11-2010 & 14/10-
1-2012 decisions. All settings needed for the study including 
consumables, equipment and substances used, were a courtesy of 
Experimental Research Center of ELPEN Pharmaceuticals Co. Inc. S.A. 
at Pikermi, Attiki. Accepted standards of humane animal care were 
adopted for Albino female Wistar rats. Normal housing in laboratory 
7 days before the experiment included continuous access to water 
and food. The experiment was acute, that means that awakening and 
preservation of the rodents was not following the experiment. They 
were randomly delivered to four experimental groups by 10 animals 
in each one. Hypoxia for 45 min followed by reoxygenation for 60 
min (group A). Hypoxia for 45 min followed by reoxygenation for 120 
min (group B). Hypoxia for 45 min followed by immediate Epo 
intravenous (IV) administration and reoxygenation for 60 min (group 
C). Hypoxia for 45 min followed by immediate Epo IV administration 
and reoxygenation for 120 min (group D). The molecule Epo dosage 
was 10 mg/Kg body weight of animals. 
At first, the animals were submitted into prenarcosis 
followed by general anesthesia. The detailed anesthesiologic 
technique is described in related references1. Oxygen supply, 
electrocardiogram and acidometry were continuously provided 
during whole experiment performance.   
The protocol of HR was followed. Hypoxia was caused by 
forceps clamping inferior aorta over renal arteries for 45 min after 
laparotomic access had been achieved. Reoxygenation was induced 
by removing the clamp and reestablishment of inferior aorta patency. 
The molecules were administered at the time of reoxygenation, 
through inferior vena cava after catheterization had been achieved. 
The albumins levels measurements were performed at 60 min of 
reoxygenation (for groups A and C) and at 120 min of reoxygenation 
(for groups B and D). The mean weight of the forty (40) female 
Wistar albino rats used was 247.7 g [Std. Dev: 34.99172 g], with min 
weight ≥ 165 g and max weight < 320 g. Rats' weight could be 
potentially a confusing factor, e.g. the more obese rats to have 
greater albumins levels. This suspicion was investigated. 
2.2 Model of hypoxia-reoxygenation injury 
Control groups: 20 control rats (mean mass 252.5 g [Std. Dev: 
39.31988 g] suffered by hypoxia for 45 min followed by 
reoxygenation.  
Group A: Reoxygenation lasted for 60 min (n=10 controls rats) mean 
mass 243 g [Std. Dev: 45.77724 g], mean albumins levels 3.55 g/dL 
[Std. Dev: 0.3308239 g/dL] (Table 2).     
Group B: Reoxygenation lasted for 120 min (n=10 controls rats) 
mean mass 262 g [Std. Dev: 31.10913 g], mean albumins levels 3.83 
g/dL [Std. Dev: 0.3917198 g/dL] (Table 2).   
Erythropoietin group: 20 Epo rats (mean mass 242.9 g [Std. Dev: 
30.3105 g] suffered by hypoxia for 45 min followed by reoxygenation 
in the beginning of which 10 mg Epo /kg body weight were IV 
administered.  
Group C: Reoxygenation lasted for 60 min (n=10 Epo rats) mean 
mass 242.8 g [Std. Dev: 29.33636 g], mean albumins levels 3.39 g/dL 
[Std. Dev: 0.2766867 g/dL] (Table 2).     
Group D: Reoxygenation lasted for 120 min (n=10 Epo rats) mean 
mass 243 g [Std. Dev: 32.84644 g], mean albumins levels 3.33 g/dL 
[Std. Dev: 0.3591657 g/dL] (Table 2).   
2.3 Statistical analysis 
Weight comparison of everyone from 4 rats groups 
initially was performed with each other from 3 remained groups 
applying statistical paired t-test (Table 3). Any emerging significant 
difference among albumins levels, was investigated whether owed in 
the above mentioned significant weight correlations. Albumins levels 
comparison of everyone from 4 rats groups initially was performed 
with each other from 3 remained groups applying statistical paired t-
test (Table 3). The application of generalized linear models (glm) 
with dependant variable the albumins levels and independent 
variables the Epo administration or no, the reoxygenation time and 
their interaction was followed. Inserting the rats’ weights as 
independent variable at glm, a non-significant relation turned on 
albumins levels (p= 0.0874), so as to further investigation was not 
needed.   
 
3. Results  
Epo administration significantly decreased the albumins 
levels by 0.33 g/dL [-0.5533603 g/dL - -0.1066396 g/dL] (P= 
0.0049). This finding was in accordance with the results of paired t-
test (p=0.0059). Reoxygenation time non-significantly increased the 
albumins levels by 0.11 g/dL [-0.1356204 g/dL - 0.3556204 g/dL] 
(P= 0.3703), in accordance also with paired t-test (P= 0.3107). 
However, erythropoietin administration and reoxygenation time 
together produced a significant combined effect in keeping decreased 
the albumins levels by 0.1909091 g/dL [-0.3268572 g/dL -0.054961 
g/dL] (P= 0.0072). Reviewing the above and table 3, the tables 4 and 
5 sum up concerning the alteration influence of Epo in connection 
with reoxygenation time.  
 
Table 2: Weight and albumin mean levels and Std. Dev. of groups 
Groups Variable Mean Std. Dev 
A Weight 243 g 45.77724 g 
Albumin 3.55 g/dL 0.3308239  g/dL 
B Weight 262 g 31.10913 g 
Albumin 3.83 g/dL 0.3917198 g/dL 
C Weight 242.8 g 29.33636 g 
Albumin 3.39 g/dL 0.2766867 g/dL 
D Weight 243 g 32.84644 g 
Albumin 3.33 g/dL 0.3591657 g/dL 
 
Table 3: Statistical significance of mean values difference for 
groups (DG) after statistical paired t test application 
DG Variable Difference p-value 
Α-Β Weight -19 g 0.2423 
Albumin -0.28 g/dL 0.1189 
A-C Weight 0.2 g 0.9900 
Albumin 0.16 g/dL 0.2500 
A-D Weight 0 g 1.0000 
Albumin 0.22 g/dL 0.0338 
B-C Weight 19.2 g 0.2598 
Albumin 0.44 g/dL 0.0170 
B-D Weight 19 g 0.1011 
Albumin 0.5  g/dL 0.0109 
C-D Weight -0,2 g 0.9883 
Albumin 0.06 g/dL 0.6275 
                                                                                              
Table 4: The decreasing influence of erythropoietin in 
connection with reperfusion time 





0.16 g/dL -0.4465275 g/dL - 
0.1265276 g/dL 
1h 0.2500 0.2560 
0.33 g/dL       -0.5533603 g/dL - 
-0.1066396 g/dL 
1.5h                 0.0059                0.0049     
0.5  g/dL      -0.8530827 g/dL - 
-0.1469173 g/dL 
2h 0.0109                 0.0081 
-0.11 g/dL    -0.1356204 g/dL - 
0.3556204 g/dL 
reperfusion 





0.054961 g/dL         
interaction      0.0072 
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Table 5: The (%) decreasing influence of erythropoietin in 
connection with reperfusion time 
Decrease +SD                              Reperfusion time                p-values   
-4.61%                                +4.21%                                   1h  0.2530            
-9.28%                                +3.20%                                 1.5h                     0.0054     
-13.96% +5.03% 2h 0.0095 
+3.09%                               +3.52%                         reperfusion time                  0.3405 
-5.37%                                +2.73%                           interaction 0.0072 
                       
4. Discussion 
A lot of clinical situations can show how ischemia 
influences the albumins levels. Liepinsh et al [2] demonstrated that 
ischemic damage is significantly lower in the fed state compared with 
fasted state in Wistar and diabetic Goto-Kakizaki rat’s hearts. Even 
overnight fasting could provoke and aggravate cardiovascular events 
and high-risk cardiovascular patients should avoid prolonged fasting 
periods. Abubakar et al [3] determined the mean serum albumin 
significantly higher by 45.67% in short-term first-ever acute stroke 
favourable outcome patients than those with unfavourable outcome 
(p=0.0001). Patients that died had significantly lower serum albumin 
(1.66 g/dl) than survivors (p=0.0001). Serum albumin of 1.55 g /dL 
has sensitivity of 100% and specificity of 61.5%. Low admission 
serum albumin was an independent determinant of poor outcome. 
Herisson et al [4] found neither difference nor correlation in 
admission baseline ischemia-modified albumin (IMA) levels within 
4.5 hours of acute ischemic and hemorrhagic stroke onset patients. 
Consuegra-Sanchez et al[5] found the 30-day combined end point 
1.48-fold (P = 0.017) and the 1-year mortality rate 1.78-fold (P = 
0.028) significantly5 higher in patients with IMA levels > 93.3 U/ml 
obtained on admission compared with lower IMA or IMA as a general 
independent predictor patients presenting to the emergency 
department with typical acute chest pain. Polk et al[6] measured 
significantly higher cobalt-albumin binding assay (CABA) test values 
by 1.67-fold in clinically diagnosed intestinal ischemia patients, than 
control patients without intestinal ischemia (p = 0.00023). This 
resulted in a sensitivity of 100% and a specificity of 85.7% for the 
CABA test, making it a useful tool for risk stratification of intestinal 
ischemia. Dusek et al [7] used a negative IMA marker as an aid to rule 
out acute coronary syndrome (ACS) in low risk symptomatic patients 
with non-diagnostic ECG and normal troponin. Worster et al[8] found 
likelihood ratios 1.35 and 0.98 for IMA < and > 80 U/mL respectively 
within 6 hours after chest pain in order to predict  a serious cardiac 
outcome within the following 72 hours, suggest IMA as a poor short 
term predictor of serious cardiac outcomes. Rafael Sadaba et al [9] 
reduced the mean tissue perfusion of the upper limb by 15.38% (P = 
0.000555) using Technetium-99m human serum albumin after 
removal of the radial artery, but did not affect short term hand 
function. Steinbauer et al [10] enhanced the half-life and antioxidant 
activity of nitroxides by their covalent binding to human serum 
albumin, resulting in polynitroxyl albumin (PNA) in an IR hamster 
dorsal skinfold chamber model. PNA in the dose 1% b.w. and--to a 
lesser extent albumin--effectively reduced postischemic 
microvascular perfusion failure, and tissue injury. Although free 
oxygen radical scavenging seems to be an underlying mechanism 
leading to the beneficial effects of PNA on IR injury, hemodilution and 
known radical scavenging properties of pure albumin contribute in 
part to the observed effects. Donaldson et al [11] explained why 
deaths from arterial disease are more prevalent in winters 
associating short-term falls in temperature with significant and 
prolonged haemoconcentration and hypertension which produce 
significant increases in serum albumin and in mortalities from 
ischemic heart disease and cerebrovascular disease. Arend et al [12] 
found similar significant decreases in serum albumin values within 
24 h in heart patients both treated and control ones with 
nitroglycerin. Pollock et al[13] produced a significant increase by 
2.05-fold nearly identical to those of atrial natriuretic factor (ANF) at 
0.5 μg/kg/min in glomerular filtration rate (GFR) administering 10 
μg/kg/min A68828 after acute renal IR failure compared with vehicle 
controls (P < 0.05). These results indicate that infusion of a reduced-
size analog of ANF, A68828ANF improves renal function in the 
immediate postischemic period in Sprague-Dawley rats. Tilton et al 
[14] decreased the rate of intravascular clearance of radiolabelled 
albumin by 36% and increased the mean transit time of the coronary 
vasculature by albumin approximately 1.875-fold in ischemic hearts 
than control hearts from rabbits fed normal chow and 2-fold increase 
prior to ischemia in rabbits fed cholesterol for 2-3 weeks.  
Also, albumines is a factor influenced by Epo 
administration. Kojima et al [15] switched patients from 
conventional in-center hemodialysis to home hemodialysis (HHD) 
improving serum albumin levels and simultaneously reducing 
erythropoietin-stimulating agent levels. Capelli et al [16] found a 
local 69.31-fold and a national 4.22-fold mortality increase for 
albumin > 4.0 than albumin <3.5 as statistically significant predictors 
of survival. These findings indicate that individually higher albumin 
levels improve the survival rates and hospitalizations for end-stage 
renal disease (ESRD) patients under erythropoietic stimulating 
agents (epoetin-α) use. Costa et al[17] found statistically significant 
differences between responders and nonresponders (resistance) to 
rhEPO therapy hemodialysis chronic kidney disease (CKD) patients 
which may be due to the erythropoiesis-suppressing effect of pro-
inflammatory cytokines, for albumin (lower in nonresponders) levels 
both compared with healthy control ones. Lin et al [18] found 
significantly increased TS at following 4 months in chronic HD 
patients with type II diabetes. Aguilera et al[19] induced a temporary, 
non inflammatory immune hyperactivity mediated by TNFα 
increasing progressively albumin 7% and short term normalized 
protein catabolic rate (nPCR) 12% daily and then decreased 
progressively albumin 5% and nPCR 5% daily too, in peritoneal 
dialysis (PD) rHuEPO (40-70 subcutaneous units/kg weekly) treated 
patients than control group. rHuEPO could increase food intake and 
improve the nutritional status of PD patients. Ortega et al [20] 
showed lower (P<0.05) albumin concentration and predicted poorer 
response to weekly Epo dose in pre-dialysis patients with higher 
prevalence of inflammation and CRP levels (>6 mg/l) at baseline. 
Rudduck et al [21] analyzed the stimulating effect of bovine serum 
albumin (BSA) and Epo on the erythroid mitoses in short-term 
marrow cultures. Krystal et al [22] reduced markedly the specific 
activities of 100-300 units of partially purified Epo urine 
preparations stored in solution in the presence of 1% bovine serum 
albumin.  
 
5. Conclusion  
Erythropoietin administration whether it interacted or not 
with reoxygenation time, has significant decreasing effects on 
albumins levels in a short-term context of 2 hours. It seems that 
starvation, or launched anabolic pathways consume albumins. 
Further human clinical or molecular studies are required to make 
this effect clearer.     
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